Kenneth Cohen to Prognosis
This is a "connection" page, showing publications Kenneth Cohen has written about Prognosis.
Connection Strength
0.302
-
A phase I trial of arsenic trioxide chemoradiotherapy for infiltrating astrocytomas of childhood. Neuro Oncol. 2013 Jun; 15(6):783-7.
Score: 0.056
-
Pediatric Central Nervous System Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 12; 20(12):1339-1362.
Score: 0.027
-
Pediatric glial tumors. Curr Treat Options Oncol. 2001 Dec; 2(6):529-36.
Score: 0.026
-
Tectal gliomas: natural history of an indolent lesion in pediatric patients. Pediatr Neurosurg. 2000 Jan; 32(1):24-9.
Score: 0.022
-
Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma. Neuro Oncol. 2018 10 09; 20(11):1547-1555.
Score: 0.021
-
Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma. Neuro Oncol. 2017 Oct 19; 19(11):1542-1552.
Score: 0.019
-
A pediatric trial of radiation/cetuximab followed by irinotecan/cetuximab in newly diagnosed diffuse pontine gliomas and high-grade astrocytomas: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study. Pediatr Blood Cancer. 2017 Nov; 64(11).
Score: 0.019
-
Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma. Neuro Oncol. 2014 Nov; 16(11):1554-9.
Score: 0.015
-
Association between radiation dose to neuronal progenitor cell niches and temporal lobes and performance on neuropsychological testing in children: a prospective study. Neuro Oncol. 2013 Mar; 15(3):360-9.
Score: 0.014
-
T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapse. Leuk Lymphoma. 2011 Feb; 52(2):214-22.
Score: 0.012
-
Spectrum of pilomyxoid astrocytomas: intermediate pilomyxoid tumors. Am J Surg Pathol. 2010 Dec; 34(12):1783-91.
Score: 0.012
-
Akt activation is a common event in pediatric malignant gliomas and a potential adverse prognostic marker: a report from the Children's Oncology Group. J Neurooncol. 2010 Sep; 99(2):155-63.
Score: 0.012
-
Prognostic factors in pediatric high-grade astrocytoma: the importance of accurate pathologic diagnosis. J Neurooncol. 2010 Aug; 99(1):65-71.
Score: 0.011
-
Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol. 2009 Jan 20; 27(3):385-9.
Score: 0.010
-
Outcome analysis of childhood low-grade astrocytomas. Pediatr Blood Cancer. 2008 Aug; 51(2):245-50.
Score: 0.010
-
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol. 2005 Nov 01; 23(31):8136-9.
Score: 0.008
-
Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol. 2004 May; 63(5):441-9.
Score: 0.008